AbbVie has partnered with preclinical oncology biotech Disco Pharmaceuticals to build out solid-tumor targets across its antibody-drug conjugate and T cell engager programs. The agreement includes a $40 million upfront payment and total potential consideration of up to $2.5 billion, according to deal terms described in the report. Disco Pharmaceuticals will contribute platform and discovery capabilities aimed at identifying and optimizing therapeutic candidates, while AbbVie focuses on downstream development and commercialization. The collaboration signals continued emphasis on expanding differentiated targeted modalities in solid tumors. For investors and competitors, the structure and scale of the transaction highlights AbbVie’s willingness to fund early-stage target programs while leveraging its internal development and clinical execution engine to move candidates through trials.
Get the Daily Brief